Log In
BCIQ
Print this Print this
 

PRCN-226

  Manage Alerts
Collapse Summary General Information
Company Neuralgene
DescriptionAAV gene therapy designed to be neurotropic
Molecular Target
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Adeno-associated virus (AAV)
Latest Stage of DevelopmentDiscovery
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat Parkinson's disease (PD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today